medigraphic.com
Revista Médica Sinergia

2020, Number 10

<< Back Next >>

Revista Médica Sinergia 2020; 5 (10)

Vaccine against human papillomavirus

Hernández PA, Araya VS

Language: Spanish
References: 18
Page: 1-9
PDF size: 168.22 Kb.


ABSTRACT

The human papilloma virus has been labeled as the first cause of cervical cancer cases in the world, that is why 3 different vaccines have been developed: the bivalent that covers against the serotypes 16 and 18, the quadrivalent for 6, 11, 16 y 18 and the nonavalent that covers against 6, 11, 16, 18, 31, 33, 45, 52 y 58; therefore, the majority of serotypes related to cancer and condylomatous injuries are covered with the vaccine. Two doses are indicated in a vaccination schedule for population among 9 and 15 years and three in the case of people among 15 and 26 years. Vaccines are secure, well tolerated and they are able to produce an accurate immune response. These do not have contraindication to be applied in immunocompromised patients but they have minor immune response than general population. Vaccines are not recommended during pregnancy but they are secure during breastfeeding. The vaccine against human papilloma virus has contributed to the reduction of illnesses associated to this virus which has evidenced its benefits in human health.


REFERENCES

  1. David Springs. Gynecologic Malignancies. En J. Larry Jameson, Anthony S., Fauci, Dennis L. Kasper., Stephen L. Hauser., Dan L. Longo., Joseph Loscalzo (editor). Harrison's Principles of Internal Medicine. 20th Edition. United States: McGraw-Hill; 2018: p. 9-13.

  2. Elmar A. Joura, M.D., Anna R. Giuliano, Ph.D., Ole-Erik Iversen, M.D., Celine Bouchard, M.D., et al. A 9- Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med [Internet]. 2015 [consultado 16 Marzo 2020]; 372(8): 711-723. https://doi.org/10.1056/NEJMoa1405044

  3. Christine Holschneider. Trastornos premalignos y malignos del cuello uterino. En Allan H. DeCherney (Editor). Diagnóstico y Tratamiento Ginecoobstétricos. 11 Edición. Ciudad de México: McGraw-Hill; 2014. p. 808-809.

  4. Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Corton MM. Williams Ginecología [Internet]. New York, NY: McGraw-Hill; 2017 [revisión2017; consultado 12 Marzo 2020]. Disponible en: https://ezproxy.ucimed.com:2066/content.aspx?bookid=2162§ionid=165579611#1144484780

  5. Lauri E. Markowitz, MD., Julianne Gee, MPH., Harrell Chesson, PhD., Shannon Stokley, DrPH. Ten Years of Human Papillomavirus Vaccination in the United States. Elsevier [Internet]. 2018 [consultado 10 Marzo 2020]; 18(2S): S3-S10. https://doi.org/10.1016/j.acap.2017.09.014

  6. Leslie L. Clark, PhD, MS., Shauna Stahlman, PhD, MPH., Stephen B. Taubman, PhD. Human Papillomavirus Vaccine Initiation, Coverage, and Completion Rates Among U.S. Active Component Service Members, 2007-2017. MSMR [Internet]. 2018 [consultado 15 marzo 2020]; 25(9):9-14. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/30272988

  7. Alain Luxembourg., Erin Moeller. 9-Valent human papillomavirus vaccine: a review of the clinical development program. Taylor & Francis [Internet]. 2017 [consultado 02 Marzo 2020]; 16 (11): 1119-1139. https://doi.org/10.1080/14760584.2017.1383158

  8. Elissa Meites, Allison Kempe, Lauri E, Markowitz. Use of a 2-Dose Schedule for Human Papillomavirus Vaccination - Updated Recommendations of the Advisory Committee on Immunization Practices. MMWR [Internet] 2016 [consultado 02 Marzo 2020]; 65(49):1405-1408. https://doi.org/10.15585/mmwr.mm6549a5

  9. Aimée R. Kreimer, Rolando Herrero, Joshua N. Sampson, Carolina Porras, Douglas R. Lowy, Jhon T Schiller, et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. ELSEVIER [Internet] 2018 [consultado 02 Marzo 2020]; 36(32): 4774-4782. https://doi.org/10.1016/j.vaccine.2017.12.078

  10. Claudia Robles, María de la Luz Hernández, Maribel Almonte. Alternative HPV vaccination schedules in Latin America. Salud Pública De México [Internet] 2018 [consultado 01 Marzo 2020]; 60(6): 693-702. https://doi.org/10.21149/9810

  11. Linda O'Neal Eckert, Anna Barbara Mosciki. Human Papillomavirus Vaccination. ACOG [Internet] 2017 [consultado 29 Febrero 2020]; 129(6): 173-178. Disponible en: https://www.acog.org/clinical/clinical guidance/ committee-opinion/articles/2017/06/human-papillomavirus-vaccination

  12. Elissa Meites, MD., Peter G. Szilagyi, MD., Harrell W. Chesson, PhD., Elizabeth R. Unger, PhD, MD., José R. Romero, MD., Lauri E. Markowitz, MD. Supplemental information and guidance for vaccination providers regarding use of 9-valent HPV. CDC [Internet]. 2019 [consultado 12 Marzo 2020]; 68(32);698-702. Disponible en https://www.cdc.gov/mmwr/volumes/68/wr/mm6832a3.htm

  13. Yoshiki Eto, Narcís Saubi, Pau Ferrer Joan Joseph. Design Chimeric Virus-Like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned. AIDSRev [Internet] 2019 [consultado 28 Febrero 2020]; 21(4): 218-232. https://doi.org/10.24875/AIDSRev.19000114

  14. Tino F. Schwarz, Li-Min Huang, Alejandra Valencia, Falko Panzer, Cheng-Hsun Chiu, Annabelle Decreux. A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years. Taylor & Francis. [Internet] 2019 [consultado 02 Marzo 2020]; 15(7-8) 1970-1979. https://doi.org/10.1080/21645515.2019.1625644

  15. Aimée R Kreimer, Ph.D., Frank Struyf, MD., Maria Rowena Del Rosario-Raymundo, MD., Prof. Allan Hildesheim, Ph.D., S Rachel Skinner, Ph.D., Prof. Sholom Wacholder, Ph.D., et al. Efficacy of Fewer than Three Doses of an HPV-16/18 AS04 adjuvanted Vaccine: Combined Analysis of Data from the Costa Rica Vaccine Trial and the PATRICIA Trial. PMC [Internet]. 2015 [consultado 07 Marzo 2020]; 16(7): 775-786. https://doi.org/10.1016/S1470-2045(15)00047-9

  16. Laia Bruni, Beatriz Serrano, Xavier Bosch, Xavier Castellsagué. Vacuna frente al Virus del papiloma Humano. Eficacia y Seguridad.ELSEVIER [Internet] 2015 [consultado 02 Marzo 2020]; 33(5): 342-354. https://doi.org/10.1016/j.eimc.2015.03.018

  17. Gina S. Ogilvie MD DrPH., Felicia Phan MPH., Heather N. Pedersen MPH., Simon R. Dobson MD., Monika Naus MD MHSc., Elizabeth M. Saewyc PhD RN. Population-level sexual behaviours in adolescent girls before and after introduction of the human papillomavirus vaccine. CMAJ [Internet]. 2018 [consultado 06 Marzo 2020]; 140(41): 1221-1226. https://doi.org/10.1503/cmaj.180628

  18. Johannes a Bogaards, Jacco Wallinga, Ruud H Brakenhoff, Chris Meijer, Johannes Berkhof. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: Bayesian evidence synthesis. BMJ [Internet] 2015 [consultado 28 Febrero 2020]; 10(1136): 1-9. https://doi.org/10.1136/bmj.h2016




2020     |     www.medigraphic.com